Results 1 to 10 of about 5,976,322 (209)

KCl-Dependent Release of Mitochondrial Membrane-Bound Arginase Appears to Be a Novel Variant of Arginase-II. [PDF]

Scientifica (Cairo), 2016
Arginase regulates arginine metabolism, ornithine-urea cycle, and immunological surveillance. Arginase-I is predominant in cytosol, and arginase-II is localised in the mitochondria.
Suman M, Rajnikant M.
europepmc   +3 more sources

p32-Dependent p38 MAPK Activation by Arginase II Downregulation Contributes to Endothelial Nitric Oxide Synthase Activation in HUVECs. [PDF]

Cells, 2020
Arginase II reciprocally regulates endothelial nitric oxide synthase (eNOS) through a p32-dependent Ca2+ control. We investigated the signaling pathway of arginase II-dependent eNOS phosphorylation. Western blot analysis was applied for examining protein
Koo BH, Won MH, Kim YM, Ryoo S.
europepmc   +3 more sources

Hypoxic Proliferation of Osteosarcoma Cells Depends on Arginase II

Cellular Physiology and Biochemistry, 2016
Background/Aims: Despite significant advancements in the diagnosis and treatment of osteosarcoma, the overall survival has remained relatively unchanged for over two decades.
Leif D. Nelin, Bhuvana A. Setty, Yi Jin, Nicholas D. Yeager, Thomas G. Gross, Peter J. Houghton   +5 more
core   +2 more sources

RETRACTED: Arginase II - a new target in the development of endothelium protectors [PDF]

Регуляторные исследования и экспертиза лекарственных средств, 2018
RETRACTED ARTICLEThe article describes arginase’s role in pathogenesis of endothelial dysfunction and a number of cardio-vascular diseases. Arginase catalyzes the hydrolysis of L-arginine, the substrate for nitric oxide synthesis, to L-ornithine and urea.
V. I. Yakushev, M. V. Pokrovsky, A. S. Litvinova, S. A. Demchenko, O. V. Myasishcheva, E. A. Beskhmelnitsyna, I. I. Krivoshapova   +6 more
core   +2 more sources

Selective Endothelial Overexpression of Arginase II Induces Endothelial Dysfunction and Hypertension and Enhances Atherosclerosis in Mice. [PDF]

PLoS ONE, 2012
Background: Cardiovascular disorders associated with endothelial dysfunction, such as atherosclerosis, have decreased nitric oxide (NO) bioavailability.
Xiao L Moore, Sidney M Morris Jr, Wood, Katherine C, Yi Fu, Vaisman Boris L., Remaley, Alan T, Katherine C Wood, Boris L Vaisman, Andrews, Karen L, Fu Yi, Vaisman, Boris L, Moore, Xiao L, Alan T Remaley, Sidney M Morris, Khong, Sacha M L, Morris Sidney M., Remaley Alan T., Sacha M L Khong, Diane M Kepka-Lenhart, *, Fu, Yi, Andrews Karen L., Khong Sacha M. L., Moore Xiao L., Kepka-Lenhart Diane M., Chin-Dusting, Jaye P F, Jaye P F Chin-Dusting, Chin-Dusting Jaye P. F., Kepka-Lenhart, Diane M, Morris, Sidney M, Wood Katherine C., Karen L Andrews   +31 more
core   +3 more sources

ENDOTHELIOPROTECTIVE AND CARDIOPROTECTIVE ACTIVITY OF SELECTIVE ARGINASE II INHIBITOR [PDF]

Кубанский научный медицинский вестник, 2015
They researched endothelioprotective and cardioprotective activity of arginase II selective inhibitor (substance code ZB49-0010C) in model of L-NAME-induced deficit of nitric oxide.
M. V. Pokrovskii, V. I. Yakushev, O. S. Gudyrev, A. S. Litvinova, M. V. Korokin, T. G. Pokrovskaya, E. A. Beskhmelnitsyna, V. V. Gureev, V. V. Elagin   +8 more
core   +2 more sources

Cardiovascular effects of an arginase II selective inhibitor [PDF]

Research Results in Pharmacology, 2016
For the first time in vitro experiments there were studied the inhibitory activity and safety of potential molecules arginase II selective inhibitors from the group of norleucine derivatives.
Pokrovskii,Mikhail, Yakushev, V. I., Pokrovskii, M. V., Pokrovskii, Mikhail, Yakushev,Vladimir, Yakushev, Vladimir   +5 more
core   +6 more sources

Possible Involvement of Altered Arginase Activity, Arginase Type I and Type II Expressions, and Nitric Oxide Production in Occurrence of Intimal Hyperplasia in Premenopausal Human Uterine Arteries

Journal of Pharmacological Sciences, 2008
In the present experiments, we tried to elucidate whether changes in arginase activity and protein expression of arginase I and II are involved in the occurrence of intimal hyperplasia in premenopausal human uterine arteries.
Hiroshi Azuma, Tomoko Ishibashi, Galina Vasileva Marinova, Toshiro Kubota, Masatoshi Imamura, Satoshi Obayashi, Renzo Ygor Loyaga-Rendon   +6 more
core   +2 more sources

Correction: angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function. [PDF]

PLoS ONE, 2015
Arterial stiffness (AS) is an independent risk factor for cardiovascular morbidity/mortality. Smooth muscle cell (SMC) proliferation and increased collagen synthesis are key features in development of AS.
Zhimin Xu, Haroldo A Toque, Anil Bhatta, Ruth B Caldwell, R William Caldwell, Lin Yao, Alia Shatanawi   +6 more
core   +2 more sources

Role of pulmonary epithelial arginase-II in activation of fibroblasts and lung inflammaging. [PDF]

Aging Cell, 2023
Elevated arginases including type-I (Arg-I) and type-II isoenzyme (Arg-II) are reported to play a role in aging, age-associated organ inflammaging, and fibrosis. A role of arginase in pulmonary aging and underlying mechanisms are not explored.
Zhu C, Potenza DM, Yang Y, Ajalbert G, Mertz KD, von Gunten S, Ming XF, Yang Z.   +7 more
europepmc   +3 more sources